{"Clinical Trial ID": "NCT00106002", "Intervention": ["INTERVENTION 1:", "- Pemetrexed", "600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression"], "Eligibility": ["Incorporation criteria:", "A diagnosis of advanced or metastatic breast cancer is required.", "- Chemotherapy has not been administered for advanced or metastatic breast cancer.", "The diagnosis of advanced or metastatic breast cancer was made at least 12 months after the administration of chemotherapy after breast surgery.", "Able to perform light work (e.g. light housework, office work).", "He must be at least 18 years old.", "- Exclusion criteria:", "Have already received a bone marrow or peripheral stem cell transplant.", "Have already received chemotherapy for metastatic breast cancer.", "Are currently pregnant or breastfeeding.", "Have an active infection that your doctor decides to affect your safety.", "Are unable to take folic acid or vitamin B12."], "Results": ["Performance measures:", "Overall response of tumours", "The best response recorded from the start of treatment to the progression or recurrence of the disease using the solid tumour response assessment criteria (RECIST), which defines when participants improve (\"response\"), remain the same (\"stable\") or worsen (\" progression\") during treatment.", "Time: every 3 cycles (approximately 6 to 7 weeks) or until the patient has a progression of the disease", "Results 1:", "Title of the arm/group: Pemetrexed", "Description of the arm/group: 600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression", "Total number of participants analysed: 35", "Type of measurement: Number", "Unit of measure: Participants Complete response: 1", "Partial reply: 8", "\u2022 Stable disease: 14", "\u2022 Progressive diseases: 9", "Best non-evaluable response: 3"], "Adverse Events": ["Undesirable Events 1:", "Total: 14", "Anemia 2/36 (5.56%)", "1/36 (2.78 per cent)", "Angina pectoris 1/36 (2.78%)", "Upper abdominal pain 1/36 (2.78%)", "Diarrhoea 1/36 (2.78%)", "Nausea 3/36 (8.33%)", "2/36 (5.56%)", "Asthenia 1/36 (2.78%)", "Fatigue 1/36 (2.78 per cent)", "Cellulite 2/36 (5.56%)", "Bacterial peritonitis 1/36 (2.78%)", "1/36 (2.78%)"]}